Table 4.
Univariate analyses of patients with or without 30% pain relief by mirogabalin
| Variables |
< 30% pain relief (n= 50) |
≥ 30% pain relief (n= 113) |
pvalue |
|---|---|---|---|
| Age (years) | 72.9 ± 11.9 (45–88) | 71.3 ± 13.0 (30–94) | 0.46a |
| Sex, female/male | 30/20 | 82/31 | 0.11b |
| Diagnosis | 0.75b | ||
| LCS | 35 | 83 | |
| CSM | 11 | 17 | |
| LDH | 2 | 7 | |
| CTS | 2 | 6 | |
| Others | 0 | 1 | |
| BMI (kg/m2) | 22.7 ± 4.2 (18–33) | 23.0 ± 3.8 (19–31) | 0.79a |
| DM | 4 | 11 | 0.72b |
| NeP score (points) | 7.4 ± 2.1 (6–12) | 6.6 ± 1.4 (6–12) | 0.0047a |
| Primary doze (mg) | 3.1 ± 1.5 (5–10) | 3.1 ± 1.1 (5–10) | 0.97a |
| Max dose (mg) | 6.6 ± 3.8 (5–30) | 6.4 ± 3.8 (5–30) | 0.76a |
| Adverse events | 24 (48%) | 42 (37.2%) | 0.13b |
| Somnolence | 17 (34%) | 27 (23.9%) | |
| Dizziness | 6 (12%) | 10 (8.8%) | |
| Edema | 2 (4%) | 5 (4.4%) | |
| Weight gain | 1 (2%) | 0 (0%) |
Data are expressed as the mean ± standard deviation (range) or n (%).
LCS lumbar canal stenosis, CSM cervical spondylotic myelopathy, LDH lumbar disc herniation, CTS carpal tunnel syndrome, BMI body mass index, DM diabetes mellitus, NeP neuropathic pain
a Student’s t-test
b Chi-squared test